GlassScriptPhysician profile
Regina T Face
NPI 1750856654
$4,623.75
in general payments reported to CMS, 2019-2025
29 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $353 · 2022: $1,551 · 2023: $978 · 2024: $1,521 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $461.36 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $409.26 | 2021-2024 | Spravato, Invega Sustenna |
| Abbvie INC. | $316.07 | 2022-2024 | |
| Novo Nordisk INC | $249.99 | 2022-2023 | Wegovy |
| Janssen Biotech, INC. | $246.07 | 2023-2024 | Erleada, Akeega |
| Ultragenyx Pharmaceutical INC. | $241.85 | 2022-2023 | Crysvita |
| Teva Pharmaceuticals USA, INC. | $229.58 | 2024 | Austedo Xr |
| Urovant Sciences INC | $224.23 | 2022 | |
| Astellas Pharma US INC | $222.80 | 2022-2024 | Veozah |
| Teleflex LLC | $212.19 | 2023-2024 | Urolift |
| Neurelis, INC. | $200.09 | 2021-2025 | Valtoco |
| Sanofi-Aventis U.S. LLC | $157.38 | 2021-2022 | |
| Coloplast Corp | $135.93 | 2022-2025 | Speedicath |
| Antares Pharma, INC. | $134.95 | 2021 | |
| 180 Medical, INC. | $125.53 | 2022-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $122.88 | 2023 | Mounjaro |
| Supernus Pharmaceuticals, INC. | $122.88 | 2024 | Qelbree |
| Acacia Pharma INC | $120.08 | 2022 | |
| Horizon Therapeutics Plc | $114.30 | 2023 | Krystexxa |
| Axsome Therapeutics, INC. | $107.40 | 2024 | Auvelity |
| Sumitomo Pharma America, INC. | $104.34 | 2024 | Orgovyx |
| Jazz Pharmaceuticals INC. | $95.95 | 2022 | |
| Medtronic, INC. | $81.36 | 2022 | |
| Boston Scientific Corporation | $73.12 | 2024 | Lithovue |
| Hollister Incorporated | $44.53 | 2022 | |
| Endo Pharmaceuticals INC. | $22.22 | 2022 | |
| Tolmar, INC. | $19.55 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $14.21 | 2022 | |
| Dentsply Ih INC. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Face listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.